Skip to main content

Advertisement

Table 1 Clinical characteristics for each patient before endoradiotherapy with amino acid co-administration

From: Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis

Patient Primary tumor ERT Sex Age (a) Weight (kg) Height (m) GFR (CKD-EPI) KDIGO Grade of CKD MAG 3 clearance ml/min/1.73 qm BSA Creatinine (mg/dl) BUN (mg/dl)
1 NET PRRT F 45 50 1.62 105 G1 236 0.7 14
2 NET PRRT M 57 58 1.71 74 G2 195 1.0 21
3 Prostate cancer RLT M 66 74 1.76 93 G1 178 0.8 16
4 Prostate cancer RLT M 76 90 1.84 83 G2 178 0.9 14
5 Prostate cancer RLT M 64 71 1.74 90 G1 252 0.9 17
6 Prostate cancer RLT M 73 75 1.74 60 G2 157 1.2 13
7 Prostate cancer RLT M 62 85 1.78 91 G1 269 0.9 13
8 Prostate cancer RLT M 73 89 1.75 74 G2 175 1.0 13
9 NET PRRT M 63 130 1.72 91 G1 253 0.9 21
10 NET PRRT M 71 102 1.84 60 G2 187 1.2 12
11 Prostate cancer RLT M 72 67 1.74 67 G2 175 1.1 28
12 NET PRRT F 54 63 1.76 84 G2 257 0.8 14
13 Prostate cancer RLT M 77 64 1.71 72 G2 224 1.0 18
14 Prostate cancer RLT M 76 66 1.89 92 G1 143 0.7 14
15 Prostate cancer RLT M 73 84 1.84 74 G2 208 1.0 17
16 Prostate cancer RLT M 57 87 1.90 112 G1 251 0.6 12
17 NET PRRT M 69 95 1.86 76 G2 233 1.0 20
18 NET PRRT M 73 86 1.80 60 G2 132 1.2 21
19 NET PRRT M 53 80 1.76 86 G2 211 1.0 17
20 NET PRRT M 59 85 1.77 55 G3 122 1.4 15
21 Prostate cancer RLT M 73 78 1.80 49 G3 129 1.4 32
22 Thyroid PRRT F 62 52 1.57 93 G1 192 0.7 9
min.     45 50 1.57 49   122 0.6 9
max.     77 130 1.90 112   269 1.4 32
mean     66 79 1.77 79   201 1.0 17
median     68 79 1.76 80   195 1.0 16
SD     08 17 0.08 16   43 0.2 5.3
  1. NET Neuroendocrine tumor, GFR glomerular filtration rate, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, MAG3 mercapto-acetyltriglycine, KDIGO Kidney Disease—Improving Global Outcomes, BUN Blood urea nitrogen